Sep 01, 2022 7:00am EDT Skye Bioscience Files Definitive Proxy Statement and Announces Stockholder Meeting Date
Aug 19, 2022 3:22pm EDT Skye Bioscience Reports that Emerald Health Therapeutics Shareholders Voted in Favor of Plan of Arrangement with Skye
Jun 30, 2022 7:00am EDT Skye Bioscience Receives Australian Ethics Committee Approval to Start First-in-Human Phase 1 Study of SBI-100 Ophthalmic Emulsion
Jun 07, 2022 7:00am EDT Skye Bioscience Expands Cannabinoid Pharmaceutical Innovation Program with Leading Cannabinoid Medicinal Chemistry Groups
May 05, 2022 7:00am EDT Skye Bioscience Reports Enhanced Intraocular Pressure-Lowering of SBI-100 Formulation Published in Peer-Reviewed Journal
Apr 28, 2022 7:00am EDT Skye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement with CMAX Clinical Research
